Poplar Therapeutics anti-IgE therapy treats atopic diseases such as food allergy, allergic asthma, and atopic dermatitis.
Poplar Therapeutics has raised $50.0M in total funding. The most recent round was Series A. The last funding was announced in January 2026.
Poplar Therapeutics's investors include SR One, Vida Ventures, Platanus.
Poplar Therapeutics is headquartered in Cambridge, United States.
Poplar Therapeutics anti-IgE therapy treats atopic diseases such as food allergy, allergic asthma, and atopic dermatitis.
Poplar Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Poplar Therapeutics — Funding & Investors." VCBacked, January 7, 2026, https://www.vcbacked.co/company/poplar-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). Poplar Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/poplar-therapeutics
{{cite web |title=Poplar Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/poplar-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated